N-甲基-2-(4-吗啉基)-1-丙胺 | 938459-08-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: N-甲基-2-(4-吗啉基)-1-丙胺
• 英文名称: N-Methyl-2-morpholin-4-ylpropan-1-amine
• CAS: 938459-08-6
• 化学式: C₈H₁₈N₂O
• 分子量: 158.244
• InChiKey: OURPSTJIJGVVIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 6-氯-苯并恶唑酮 、 N-甲基-2-(4-吗啉基)-1-丙胺 以 甲醇 为溶剂， 反应 1.0h， 生成 6-chloro-3-((methyl(2-morpholinopropyl)amino)methyl)benzo[d]oxazol-2(3H)-one
  参考文献：
  名称：

  Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening

  摘要：

  The elongation condensing enzymes in the bacterial fatty acid biosynthesis pathway represent desirable targets for the design of novel, broad-spectrum antimicrobial agents. A series of substituted benzoxazolinones was identified in this study as a novel class of elongation condensing enzyme (FabB and FabF) inhibitors using a two-step virtual screening approach. Structure activity relationships were developed around the benzoxazolinone scaffold showing that N-substituted benzoxazolinones were most active. The benzoxazolinone scaffold has high chemical tractability making this chemotype suitable for further development of bacterial fatty acid synthesis inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.033

文献信息

• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• [EN] METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT DE TROUBLES D'UTILISATION D'ALCOOL ET DE MALADIES ASSOCIÉES
  申请人：PHARMATROPHIX INC

  公开号：WO2018039641A1

  公开（公告）日：2018-03-01

  Methods and compounds for treating alcohol use disorder and associated diseases. Included is the administering to a subject in need there of an effective amount of a compound having a modulating effect on p75NTR.

  治疗酒精使用障碍和相关疾病的方法和化合物。包括向需要的受试者施用对p75NTR具有调节作用的化合物的有效量。
• [EN] TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2<br/>[FR] DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE UTILES EN TANT QU'INHIBITEURS DE DIACYLGLYCÉRIDE O-ACYLTRANSFÉRASE 2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016036636A1

  公开（公告）日：2016-03-10

  The present invention relates to a compound represented by formula I:and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ("DGAT2") and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardio renal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

  本发明涉及一种由式I表示的化合物及其药学上可接受的盐。式I的化合物是二酰甘油O-酰基转移酶2（“DGAT2”）的抑制剂，可能在治疗、预防和抑制由DGAT2介导的疾病中有用。本发明的化合物可能在治疗肝脂肪变性、糖尿病、肥胖、高脂血症、高胆固醇血症、动脉粥样硬化、心脏肾脏疾病（如慢性肾脏疾病和心力衰竭）以及相关疾病和病况中有用。
• AMINOALKYL-SUBSTITUERTE VERBINDUNGEN ALS HIF-INHIBITOREN
  申请人：Bayer Schering Pharma Aktiengesellschaft

  公开号：EP2356114A1

  公开（公告）日：2011-08-17
• TETRAHYDROISOQUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF DIACYLGLYCERIDE O-ACYLTRANSFERASE 2
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3188730B1

  公开（公告）日：2019-05-01